Provided by Tiger Trade Technology Pte. Ltd.

Erasca, Inc.

15.88
-0.1500-0.94%
Post-market: 16.520.6354+4.00%19:30 EDT
Volume:2.88M
Turnover:46.19M
Market Cap:5.55B
PE:-16.35
High:16.54
Open:16.05
Low:15.87
Close:16.03
52wk High:24.28
52wk Low:1.53
Shares:349.76M
Float Shares:291.15M
Volume Ratio:0.64
T/O Rate:0.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9710
EPS(LYR):-0.4393
ROE:-78.25%
ROA:-21.39%
PB:15.35
PE(LYR):-36.15

Loading ...

Erasca to Present Updated Phase 1 Auroras-1 Monotherapy Data for ERAS-0015 at ENA Symposium

Reuters
·
Sep 10

Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium

GlobeNewswire
·
Sep 10

Erasca to Present at Morgan Stanley Global Healthcare Conference

Reuters
·
Sep 08

J.P. Morgan Keeps Their Buy Rating on Erasca (ERAS)

TIPRANKS
·
Sep 02

Erasca Wins FDA Fast Track for Pancreatic Therapy

TIPRANKS
·
Aug 24

Erasca Says FDA Grants Fast-Track Status to ERAS-0015 for Metastatic Pancreatic Cancer

Reuters
·
Aug 24

Erasca, - Plans Three Potentially Registration-Enabling Trials for Eras-0015 in Pancreatic and Lung Cancers

THOMSON REUTERS
·
Aug 24

Erasca, - Additional Phase 1 Data for Eras-0015 Expected in H1 2027

THOMSON REUTERS
·
Aug 24

Erasca Granted FDA Fast Track Designation for Pan-Ras Molecular Glue Eras-0015 in Patients with Metastatic Pancreatic Adenocarcinoma

THOMSON REUTERS
·
Aug 24

Erasca Price Target Raised to $20.00/Share from $18.00 by B of a Securities

Dow Jones
·
Aug 15

BofA Adjusts Price Target on Erasca to $20 From $18

MT Newswires Live
·
Aug 14

Inhibrx Biosciences Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 14

Erasca Price Target Raised to $21.00/Share from $20.00 by Guggenheim

Dow Jones
·
Aug 13

Erasca Files Form 3 for President, R&D Charles S. Fuchs

Reuters
·
Aug 13

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

GlobeNewswire
·
Aug 12

Sutro Biopharma Q2 Revenue Misses Estimates, Posts Wider Loss

Reuters
·
Aug 12

Erasca Rilis Presentasi Korporat Soal Pengembangan Terapi Kanker Berbasis Jalur Ras/mapk

Reuters
·
Aug 12

Erasca, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Erasca Q2 EPS $(0.14) Misses $(0.11) Estimate

Benzinga Earnings
·
Aug 12

Earnings Flash (ERAS) Erasca Posts Q2 Loss $0.14 per Share, vs. FactSet Est of $0.11 Loss

MT Newswires Live
·
Aug 12